These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25151571)

  • 1. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
    Lee MY; Kang HJ; Park SY; Kim HL; Han E; Lee EK
    Clin Ther; 2014 Sep; 36(9):1183-94. PubMed ID: 25151571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia.
    Dasta JF; Sundar S; Chase S; Lingohr-Smith M; Lin J
    Hosp Pract (1995); 2018 Oct; 46(4):197-202. PubMed ID: 30045645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
    Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
    Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on tolvaptan for the treatment of hyponatremia.
    Dasta JF; Chiong JR; Christian R; Friend K; Lingohr-Smith M; Lin J; Cassidy IB
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):399-410. PubMed ID: 22971027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyponatremia in heart failure.
    Farmakis D; Filippatos G; Parissis J; Kremastinos DT; Gheorghiade M
    Heart Fail Rev; 2009 Jun; 14(2):59-63. PubMed ID: 18758941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia.
    Amin AN; Ortendahl JD; Harmon AL; Kamat SA; Stellhorn RA; Chase SL; Sundar SV
    Curr Med Res Opin; 2018 Mar; 34(3):559-566. PubMed ID: 29297709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
    Chiong JR; Kim S; Lin J; Christian R; Dasta JF
    J Med Econ; 2012; 15(2):276-84. PubMed ID: 22111754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.
    Liu YH; Han XB; Fei YH; Xu HT
    Medicine (Baltimore); 2017 Dec; 96(52):e9539. PubMed ID: 29384972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
    Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.